Drug Profile
Research programme: NNR modulators - GlaxoSmithKline/Targacept
Latest Information Update: 23 Oct 2012
Price :
$50
*
At a glance
- Originator Targacept
- Class Small molecules
- Mechanism of Action Nicotinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Pain; Parkinson's disease; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 04 Mar 2011 The strategic alliance between Targacept and GlaxoSmithKline terminates, effective May 2011
- 06 May 2008 Targacept selects a lead compound for development in smoking cessation triggering a milestone payment from GlaxoSmithKline
- 11 Dec 2007 A lead candidate from this research programme, TC 6499, enters clinical development